Methods, products and treatments for diabetes

A method of evaluating a treatment for regulating blood sugar levels comprising:

• obtaining a first level of K41-glycated CD59 from a first sample obtained from a subject undergoing treatment for regulating blood sugar levels,
• obtaining a second level of K41-glycated CD59 from a second sample obtained from the subject at least one day after obtaining the first level,
• comparing the first level to the second level as an indication of evaluation of the treatment.

A method of selecting a treatment for regulating blood sugar levels in a subject comprising:

• obtaining a level of the amount of K41-glycated CD59 from a sample obtained from the subject, and
• selecting the treatment for regulating blood sugar levels in the subject based at least in part on the level obtained.

A method for determining regression, progression or onset of a condition characterized by abnormal levels of glycated protein comprising;

• obtaining a level of the amount of K41-glycated CD59 from a sample obtained from a subject, and
• comparing the level to a control as a determination of regression, progression or onset of the condition.

A method of treating a subject to reduce the risk of or progression of a disorder associated with abnormally high levels of K41-glycated CD59 comprising:

• selecting and administering to a subject who is known to have an abnormally high level of K41-glycated CD59 an agent for reducing K41-glycated CD59 levels in an amount effective to reduce K41-glycated CD59 levels.

A composition of matter comprising:

• isolated K41-glycated CD59.

A composition of matter comprising:

• pure K41-glycated CD59 or a fragment thereof, wherein the fragment comprises at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous amino acids having a consecutive sequence found in CD59 and including K41, wherein K41 is glycated.

An agent that binds specifically to K41-glycated CD59 but not to K41-nonglycated CD59.